Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 19 of 25, showing 10 Applications out of 241 total, starting on record 181, ending on 190

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

181.

ECCT/21/07/03   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Fredrick Sirwa Chite
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
08-11-2021 View

182.

ECCT/21/11/08   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Videlis N Nduba
2. Prof. Jessie N Githanga
3. Fredrick Sirwa Chite
4. Bernhards Ragama Ogutu
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
3. Gertrude’s Children’s Hospital. (Nairobi City county)
4. Strathmore University Medical Centre (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
02-02-2022 View

183.

ECCT/21/11/04   GBT_131 Inclacumab-Ps 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises   
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Prof Jessie N Githanga
3. Bernhards Ragama Ogutu
4. Videlis N Nduba
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. Strathmore University Medical Centre (Nairobi City county)
 
21-12-2021 View

184.

ECCT/21/12/05   131 Inclacumab Ph 3 Trial.
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N Nduba
4. Prof. Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Gertrude’s Children’s Hospital. (Nairobi City county)
5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
 
22-03-2022 View

185.

ECCT/24/08/06   KALUMA Study
    A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment    
Principal Investigator(s)
1. Dr Patricia Odera Ojwang
2. Dr. Bernhards Ogutu
3. Dr.Bernhards Ogutu
Site(s) in Kenya
1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county)
2. Site 1601:Kombewa Clinical Research Centre (Kisumu county)
3. Ahero Clinical Trial Unit (Kisumu county)
 
26-01-2025 View

186.

ECCT/19/10/01   AMC-099
    A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)   
Principal Investigator(s)
1. ELKANAH ORANGO OMENGE
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTER
 
01-04-2020 View

187.

ECCT/11/10/04   Treatment of Advanced AIDS-KS in Resource-Limited Settings
    A5263/AMC 066 "A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
07-08-2012 View

188.

ECCT/10/11/06   Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy
    A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Walter Reed Project Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
04-08-2010 View

189.

ECCT/12/04/03   SELECT (SEcond-Line Effective Combination Therapy)
    A5273: Multicenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
22-11-2010 View

190.

ECCT/12/04/02   Short-course RPT/INH for latent TB in HIV-infected individuals
    A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection       
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
11-05-2011 View